全球多发性肌炎治疗市场 – 行业趋势和 2030 年预测

多发性肌炎治疗市场分析和规模

预计多发性肌炎治疗市场将在预测期内出现显著增长。慢性肌肉炎症病例的增加推动了多发性肌炎治疗市场的发展。有肌营养不良症家族史和存在某些影响肌肉的神经疾病的人也促进了多发性肌炎治疗的增长。持续的疫情正在显著改变制药和医疗保健行业的动态。

Data Bridge Market Research 分析了 2022-2029 年预测期内多发性肌炎治疗市场的增长率。在上述预测期内，多发性肌炎治疗市场的预期复合年增长率趋于 3% 左右。2022 年市场价值为 1 亿美元，到 2030 年将增长至 1.2668 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

多发性肌炎治疗市场范围和细分

Market Definition

Polymyositis is an uncommon, rare, autoimmune disease that affects the body's muscles and weakens them. The disease inflames muscles and other related body tissue such as blood vessels. There is no permanent cure for the disease, but a treatment may decrease the symptoms. It usually affects adults post 30 years of age.

Global Polymyositis Treatment Market Dynamics

Drivers

• Increase in Autoimmune Disorders

According to the National Institute of Environmental Health Sciences, more than 80 autoimmune diseases have been identified namely diabetes (type 1), multiple sclerosis, muscular dystrophy, rheumatoid arthritis, lupus, and celiac disease. An increase in the occurrence of these diseases drives the global polymyositis treatment market. This boosts the growth of the market.

• Rising Demand for Oral Drugs

Oral drugs is projected to boost the market growth. Oral form of drugs are very much feasible and becomes very convenient for patients. Majority of the products are available in capsule form and tablet form and it is a very viable route of administration.

Opportunities

• Rise in Elderly Population

Several studies have shown that elderly population is more prone to suffer from this disease. As per the Aging World reports from 2015, there were around 562 million people 65 and older worldwide, which increased the disease's incidence and fuelled the growth of the polymyositis treatment market.

• Increasing Demand for Retail Pharmacies

The rise in the number of polymyositis therapeutics delivered through retail pharmacies and the surge in the number of retail pharmacies in established countries create opportunities for the market growth. Furthermore, patients favour retail pharmacies for purchasing drugs, as these are easily available.

 Restraints/Challenges

• Limited Studies and Surveys

There are very few studies and surveys that is impeding the growth of the market. Only a nominal amount of data are available concerning the studies. A few studies are mainly focused on groups from a single hospital wherein only a limited patients are witnessed. Thus, this hampers the growth of the market.

• High Cost

The huge expenditure that is associated with polymyositis treatment medications hamper the market growth. This disease involves treatment with corticosteroids, different immunosuppressive agents which demands huge expenditure. This acts as a major hindrance for the market.

This polymyositis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the polymyositis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Polymyositis Treatment Market         

COVID-19 has left a major global public health crisis that has impacted practically every business. Its long-term consequences are expected to influence industry growth during the forecast period. It has been witnessed that COVID-19 can induce a systemic inflammatory response, and its clinical appearances are different. It has been stated that COVID-19 patients may develop myositis and interstitial pulmonary disease similar to polymyositis treatment.

In the post-pandemic era, the market is projected to rise because of the availability of diverse treatment options such as anti-inflammatory therapy may be beneficial to patients. Other than that, physical therapy, heat therapy are also helpful.

Global Polymyositis Treatment Market Scope

The polymyositis treatment market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Immunosuppressant
• Immunoglobulins
• Corticosteroids
• Alkylating agents
• Monoclonal antibodies

Route of Administration

• Oral
• Topical
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Polymyositis Treatment Market Regional Analysis/Insights

The polymyositis treatment market is analyzed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

多发性肌炎治疗市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于医疗保健和研发支出的增加以及熟练专业人员的存在，预测期内北美多发性肌炎治疗市场一直呈现积极增长。

由于炎症性疾病的增加、通过广告和媒体对关节疾病的认识的提高以及该地区医疗保健基础设施的迅速改善，亚太地区在市场中占据主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球多发性肌炎治疗市场份额分析

多发性肌炎治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对多发性肌炎治疗市场的关注有关

多发性肌炎治疗市场的主要参与者包括：

• 诺华公司（瑞士）
• Endo International Inc（爱尔兰）
• 梯瓦制药工业有限公司 (以色列)
• Glenmark 制药有限公司（印度）
• Cipla Inc（印度）
• Dr Reddy's Laboratories Ltd（印度）
• 雅培（美国）
• F. Hoffmann-La Roche Ltd（瑞士）
• 辉瑞公司 (美国)
• Zydus 集团 (印度)
• 鲁冰花（印度）
• Bausch Health Companies Inc.（加拿大）
• Amorphex Therapeutics Holdings, Inc（美国）
• Bausch Health Companies Inc.（美国）
• Accord Healthcare（英国）
• 基因泰克公司（美国）
• 强生服务公司（美国）
• 百时美施贵宝公司 (美国)
• 葛兰素史克公司 (英国)
• Merz Pharma（德国）
• Akorn 公司（美国）

SKU-56110